Unknown PHASE4 INTERVENTIONAL 2-arm NCT01620684

Cortisol and Nutritional Sympathetic Responsiveness

The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome

Sponsor: Baker Heart Research Institute

Conditions Insulin Resistance Metabolic Syndrome Obesity

Interventions metyrapone placebo

Updated 5 times since 2017 Last updated: Sep 8, 2014 Started: Feb 28, 2013 Primary completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Insulin Resistance and Metabolic Syndrome and is currently ongoing. Baker Heart Research Institute leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baker Heart Research Institute

Data source: Baker Heart Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Prahran, Melbourne, Australia